The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Selecting individuals for lung cancer screening based on life expectancy
Kevin ten Haaf, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, comments on how clinicians should consider the life expectancy of individuals when screening for lung cancer. Whilst there is uncertainty about how long a patient will live and that their life expectancy may be over- or underestimated, healthcare professionals need to have a certain level of confidence in determining the life expectancy for individuals in the clinic. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
